• About us

Mariposa Therapeutics is dedicated to the discovery and development of therapies for keratin related diseases. Keratin is the main structural protein in your skin. It maintains its rigidity and helps with the barrier protection that the skin offers. 

Dysregulation of keratins gives rise to multiple diseases, characterised by loss of skin integrity, blistering and hyperkeratosis, and can predispose inflammatory disorders of internal organs. Together keratin-related diseases, including Epidermolysis Bullosa Simplex, Pachyonychia congenita and psoriasis, represent a huge disease burden for patients and their families. 

Mariposa’s first product MP5219 is a disease modifying therapeutic for the first keratinopathy to be identified – Epidermolysis Bullosa Simplex (EBS).


To give people with skin diseases and their families a normal, pain-free life.

To be a global leader in the development of treatments for keratin related skin disorders.

The Team

Mariposa’s leadership combines expert generalist business acumen and specific functional expertise in biotech, with an extensive understanding of the drivers and capabilities needed for successful drug development. 

Thomas Hafner Executive Chairman
Dr. Bill Pigg Executive Director
Carin Beumer Non-executive Director
Dr. Robyn Hickerson Scientific Advisor
Dr. Phil Dudfield Technical Advisor
Damian Marron Non-Executive Director
Professor Adrian Heagarty Clinical Advisor
Investors & Collaborators

Mariposa’s pre-seed funding comes from Neem Biotech in Wales and the EB Research Partnership, based in the USA. EBRP is a highly motivated funding partner with a strong commitment to finding a solution for Epidermolysis Bullosa Simplex.

If you are interested in joining us on our mission, please contact us.